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Abstract
The ability of the pathogenic yeast Candida albicans to interconvert between budded and hyphal growth states, herein
termed the budded-to-hyphal transition (BHT), is important for C. albicans development and virulence. The BHT is under the
control of multiple cell signaling pathways that respond to external stimuli, including nutrient availability, high temperature,
and pH. Previous studies identified 21 small molecules that could inhibit the C. albicans BHT in response to carbon limitation
in Spider media. However, the studies herein show that the BHT inhibitors had varying efficacies in other hyphal-inducing
media, reflecting their varying abilities to block signaling pathways associated with the different media. Chemical epistasis
analyses suggest that most, but not all, of the BHT inhibitors were acting through either the Efg1 or Cph1 signaling
pathways. Notably, the BHT inhibitor clozapine, a FDA-approved drug used to treat atypical schizophrenia by inhibiting G-
protein-coupled dopamine receptors in the brain, and several of its functional analogs were shown to act at the level of the
Gpr1 G-protein-coupled receptor. These studies are the first step in determining the target and mechanism of action of
these BHT inhibitors, which may have therapeutic anti-fungal utility in the future.
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Introduction
Candida albicans is the most common causative agent of systemic
human fungal infections [1]. It is a major opportunistic pathogen
of immunosuppressed hosts, including AIDS patients and those
undergoing chemotherapy or tissue transplants. In addition, C.
albicans is the fourth leading cause of nosocomial bloodstream
infections, especially in patients with indwelling medical devices
[2]. Therefore, insights into the mechanisms by which C. albicans
causes disease are likely to lead to the development of new
prophylactic and therapeutic strategies.
C. albicans cells exist in different morphological and developmen-
tal states, including a budded (yeast-like) form and both pseudohy-
phal and true hyphal filamentous forms. The ability to switch
between budded and hyphal morphological states, referred herein
as the budded-to-hyphal transition (BHT), occurs in response to a
variety of external signals including elevated temperature or pH,
nitrogen and/or carbon starvation, and the presence of host
macrophages [3–5]. The most potent inducer of the BHT is growth
in complex media containing 10% serum at 37uC, however the
precise component of serum responsible for the induction is
unknown. Growth in other nutrients such as N-acetylglucosamine
(GlcNAc), methionine, or proline, or in nutrient-poor media such as
Lee’s, Spider, and low-nitrogen SLAD media [6,7] can also induce
the BHT. The BHT is also affected in response to alkaline pH,
osmotic stress and reactive oxygen species (ROS), suggesting that
BHT induction mimics a stress response in many regards.
Multiple intracellular signaling pathways respond to these
different growth and environmental signals to induce or repress
hyphal development [8–10] (Fig. 1A). Each of these pathways
activates different transcription factors (Fig. 1A, square boxes) that
induce expression of hyphal-specific genes. C. albicans cells respond
to temperature, serum, and glucose through the Ras1 GTPase
[11,12]. Activated GTP-bound Ras1 interfaces with two signaling
pathways: the Cek1 MAP kinase pathway and the protein kinase A
(PKA) pathway (Fig. 1A). The Cek1 MAPK pathway signals to the
Cph1 transcription factor [7,13–15], whereas the cAMP-PKA
pathway signals to the Efg1 transcription factor. Ras1 activates
adenylyl cyclase (Cyr1), generating a cAMP signal that leads to the
activation of the Tpk1 and Tpk2 catalytic subunits of PKA [16],
which in turn phosphorylate and activate the Efg1 transcription
factor [17,18]. The Efg1 pathway is also responsive to certain
amino acids, such as methionine, and carbon deprivation (i.e.,
growth on Spider media) through the Gpr1 G-protein-coupled
receptor and its G-alpha subunit Gpa2 [19–22].
The BHT is also induced by GlcNAc through the GlcNAc
transporter Ngt1 [23] and an ill-defined signaling pathway that
activates the Cph1 transcription factor [24,25]. The Cph2 and
Tec1 transcription factors respond to a variety of growth media
including the amino acids in Lee’s media [26–29]. Cells respond to
changes in pH through the Rim101 transcription factor [30,31].
While these pathways can be activated by separate but
overlapping developmental signals, the cross-talk between the
pathways has not been fully elucidated. The Tup1 BHT repressor
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regulators, Nrg1, Mig1, and Rfg1 to repress the BHT [32–34].
However, for the purposes of this study, we focused on signaling
pathways that induce (not repress) the BHT, as the inhibitors we
have identified most likely function through blocking one or more
of these pathways.
Previously, we identified five novel small molecules and 16
molecules with known mammalian targets or mechanisms of
action that could inhibit the BHT without affecting budded
growth [35,36]. The known molecules affect various signaling
pathway components in mammalian cells, including those
involved in calcium homeostasis, cAMP-dependent protein kinase
(PKA) and other kinases, G-protein-coupled receptors and other
receptors, Ras GTPase signaling, and other signaling proteins
[36]. This is particularly encouraging as the roles of PKA, the
G-protein-coupled receptor Gpr1, and the Ras1 GTPase in the
Efg1 pathway are well established [11,16,19] (Fig. 1A). The BHT
inhibitors were identified in assays utilizing carbon-limiting Spider
media as a hyphal-inducing signal, which impinges on the Efg1
signaling pathway, suggesting that the BHT inhibitors were
affecting this signaling pathway. This hypothesis was supported by
hyphal-specific gene expression assays using a GFP reporter
expressed under the control of the HWP1 promoter (HWP1pr-
GFP; [37]). HWP1 expression is regulated primarily through the
Efg1 signaling pathway [38], and all the BHT inhibitors, except
GW 5074, could inhibit HWP1pr-GFP expression [35,36].
The effects of a subset of the BHT inhibitors (Fig. 1B) in
different hyphal-inducing media, as well as in chemical epistasis
experiments with constitutively active mutants, were determined in
order to address the specific signaling pathways affected by these
Figure 1. BHT pathways and inhibitors. A, Morphological signaling pathways in C. albicans. For simplicity, only the Efg1, Cph1, Cph2/Tec1, and
Rim101 pathways are shown. B, BHT inhibitors used in this study.
doi:10.1371/journal.pone.0025395.g001
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primarily affect the Efg1 pathway but some have effects on other,
or multiple, pathways. Of particular note is clozapine, a FDA-
approved anti-psychotic drug that inhibits dopamine receptors in
the brain [39]. Dopamine receptors belong to the family of G-
protein-coupled receptors that regulate cAMP levels in mamma-
lian cells [40]. Various clozapine metabolites and functional
derivatives are also able to inhibit the BHT, with the likely site of
action being the G-protein-coupled receptor Gpr1, which
mediates a nutrient response through the cAMP-dependent Efg1
signaling pathway.
Results
Effects of BHT inhibitors in hyphal-inducing media
The effects of 12 BHT inhibitors (Fig. 1B) were tested under
different hyphal-inducing conditions. The hyphal-inducing media
used were (i) carbon-limiting Spider media (the original screening
media); (ii) complex YPD media+10% serum; (iii) minimal amino
acids Lee’s media; and (iv) minimal media containingGlcNAcas the
sole carbon source. All of the inhibitors were effective in Spider
media (as previously reported; [36]), but none were effective in
YPD+10% serum (Fig. 2), which may be the result of lipid-binding
serum constituents binding and inactivating the BHT inhibitors.
CGP-37157, FK-506, and ETYA were equally effective in Spider,
Lee’s,andGlcNAcmedia,suggesting that thesemolecules areeither
not affecting a specific nutrient-signaling pathway or inhibiting a
common component of multiple signaling pathways. TMB-8,
nigericin, GW-9662, and GW 5074 were the only other molecules
that were effective in Lee’s media; these molecules may inhibit an
upstream component of the Cph2/Tec1 pathway. L-744,832 was
the only other BHT inhibitor capable of blocking GlcNAc-induced
BHT, suggesting that this molecule may affect a component of this
ill-defined pathway. These data suggest that although all the
inhibitors are affecting the Efg1 pathway, which is not surprising
given that the original screen was in Spider media, some of the
inhibitors have effects on other signaling pathways as well.
Chemical epistasis studies
Chemical epistasis studies were used to determine if a BHT
inhibitor acted at a particular step in a signaling pathway. This
method involved combining an inhibitor with a constitutively
active mutant within a pathway. The phenotype of the inhibitor
(budded growth) is opposite of the phenotype of a constitutively
active mutant (hyphal growth). When combined, if the new
observed phenotype is that of the constitutively active mutant, then
the mutant is epistatic to the inhibitor and, hence, the inhibitor
likely acts upstream of the mutant in the signaling pathway.
However, if the new observed phenotype is that of the inhibitor,
then the inhibitor is epistatic to the constitutively active mutant,
suggesting that the inhibitor acts downstream of the mutant or in
another pathway.
Since all of the BHT inhibitors are predicted to inhibit the Efg1
pathway, the first chemical epistasis experiments were performed
with the constitutively active phosphomimic efg1-T206E mutant.
The Efg1 transcription factor is regulated by cAMP-dependent
protein kinase A (PKA) [41], which is encoded by two catalytic
subunits in C. albicans, Tpk1 and Tpk2 [16,42]. Efg1 contains a
PKA consensus phosphorylation site at Thr206 and the phospho-
mimic efg1-T206E mutation was constitutively active, displaying a
hyperfilamentation phenotype [41], suggesting that phosphoryla-
tion of Efg1 at Thr206 was important for induction of the BHT.
This hyperfilamentation phenotype was observed versus the
SC5314 wild-type strain (Fig. 3A, DMSO control, 79% vs. 54%;
P,0.05). Therefore, observation of the efg1-T206E constitutive
hyperfilamentation mutant phenotype in the presence of a BHT
inhibitor would suggest that the inhibitor acts upstream of Efg1 in
the pathway.
CGP-37157, ETYA, nigericin, and FK-506 were epistatic to the
constitutively active efg1-T206E mutant (i.e., displayed a budded
phenotype) (Fig. 3A), which suggested that these BHT inhibitors
either act in other signaling pathways, as was predicted from the
hyphal-inducing media studies (see above), or downstream of Efg1.
The efg1-T206E mutant was epistatic to the remainder of the BHT
inhibitors tested (Fig. 3A). These data suggested that these
molecules may act upstream of the Efg1 transcription factor.
If these BHT inhibitors were only affecting the Efg1 signaling
pathway, then overexpression of the Cph1 transcription factor in
the Cek1 MAPK pathway (Fig. 1B) would be predicted to have
little or no effect on the BHT inhibitor activity. Overexpression of
the Cph1 transcription factor under the control of the constitutive
ADH1 promoter (ADH1pr-CPH1; [13]) had no statistically
significant effect on the inhibitory activity of CPG-37157,
clozapine, GW-9662, L-744,832, GW 5074, YC-1, and ETYA
(Fig. 3B), reinforcing the notion that CPG-37157 and ETYA
inhibit other signaling pathways (see above) and that clozapine,
GW-9662, L-744,832, GW 5074, and YC-1 act primarily through
the Efg1 pathway. Overexpression of Cph1 suppressed the effects
of TMB-8, W-7, FK-506, nigericin, and A-3, suggesting that these
BHT inhibitors may be affecting components of the Cph1
pathway.
Given that clozapine, GW-9662, L-744,832, GW 5074, and
YC-1 may act upstream of Efg1, possibly at the level of the PKA
subunits or Cyr1/adenylyl cyclase, similar epistasis experiments
were performed using added db-cAMP. Addition of 10 mM N
6,29-
O-dibutyryl-cAMP (db-cAMP), a non-metabolizable derivative of
cAMP, resulted in increased filamentation (DMSO control,
Fig. 4A), and was epistatic to the addition of clozapine, GW
5074, and YC-1, but had no effect on CGP-37157 and ETYA
inhibitory activity (Fig. 4A). There was an effect of added db-
cAMP on GW-9662 and L-744,832 treated cells, but it was not
statistically significant. These data suggest that clozapine, GW
5074, YC-1 and possibly GW-9662 and L-744,832 act upstream of
adenylyl cyclase in the pathway.
The Ras1 GTPase controls the Efg1 pathway independently of
the Gpr1 receptor and it also regulates the Cek1 MAPK pathway
leading to activation of the Cph1 transcription factor (Fig. 1A).
The constitutively active ras1-G13V mutant [11] displayed
increased filamentation (DMSO control, Fig. 4B) that was epistatic
to addition of clozapine, GW-9662, L-744,832, YC-1 and
surprisingly ETYA, but not CGP-37157 or GW5074 (Fig. 4B).
These data suggest that clozapine, GW-9662, L-744,832, and YC-
1 may act upstream of Ras1. ETYA was epistatic to the efg1-
T206E mutant and added db-cAMP but not to the ras1-G13V
mutant, suggesting that ETYA is acting upstream of Ras1 but not
through the Efg1 pathway.
The G-protein coupled receptor Gpr1 interacts with the G-alpha
subunit Gpa2 to mediate glucose-limiting hyphal-inducing signals in
the Efg1 signaling pathway. Overexpression of Gpr1 under the
control of the constitutively active ADH1 promoter leads to
hyperfilamentation on solid Spider media, but not liquid media,
whereas expression of the constitutively active gpa2-Q355L mutant
results in increased filamentation in liquid Spider media [19]. If the
BHT inhibitors act through inhibition of Gpr1, then the
combination of the BHT inhibitor with ADH1pr-GPR1 should
show a lack of hyperfilamentation on solid Spider media, and
combination with the gpa2-Q355L mutant should show a hyperfi-
lamentation phenotype in liquid Spider media. The gpa2-Q355L
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but not L-744,832 (Fig. 5A), suggesting that clozapine, GW-9662,
and YC-1 may act upstream of Gpa2, presumably at the level of the
Gpr1 G-protein coupled receptor and L-744,832 acts at the level
between Ras1and Gpa2.The gpa2-Q355L mutant was alsoepistatic
to the addition of ETYA as was the ras1-G13V mutant, suggesting
that EYTA may have an effect upstream of Ras1 and Gpa2 that is
independent of the Efg1 pathway.
Figure 2. BHT inhibition in different hyphal-inducing media. Wild-type strain SC5314 was grown in the four different hyphal-inducing media
for 6 h at 37uC. At least 100 cells were counted for each sample in duplicate and all assays were repeated at least twice. Standard deviations are
shown for each sample. Asterisks indicates a P value of ,0.05 compared to the DMSO control.
doi:10.1371/journal.pone.0025395.g002
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overexpression of GPR1 under the control of the ADH1 promoter
(ADH1pr-GPR1) does leads to a hyperfilamentation phenotype on
solid Spider media [19]. Interestingly, addition of clozapine can
reverse this hyperfilamentation phenotype on solid media (Fig. 5B),
suggesting that clozapine can inhibit the function of the Gpr1 G-
protein coupled receptor.
Activity of clozapine derivatives on the BHT
Clozapine inhibited HWP1pr-GFP expression [36] and blocked
the hyperfilamentation associated with GPR1 overexpression
(Fig. 5B), suggesting that clozapine is inhibiting the Efg1 signaling
pathway at the level of the Gpr1 receptor. Clozapine is an FDA-
approved anti-psychotic drug that inhibits G-protein-coupled
dopamine receptors. Commercially available structural derivatives
Figure 3. Chemical epistasis with efg1-T206E mutant and ADH1pr-CPH1 overexpression. A, Wild-type strain SC5314 (white bars) and efg1-
T206E mutant strain AV55 (black bars) were grown in Spider media with the indicated BHT inhibitors (100 mM final concentration) for 6 h at 37uC
prior to quantification of morphological phenotype as in Figure 2. Asterisks indicates a P value of ,0.05 compared to the corresponding wild-type
SC5314 plus BHT inhibitor control. B, ADH1pr-CPH1 strain CDH72-1 was assayed in the presence of the indicated BHT inhibitors as in A. Asterisks
indicates a P value of ,0.05 compared to the wild-type SC5314 plus BHT inhibitor control.
doi:10.1371/journal.pone.0025395.g003
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structural determinants necessary for clozapine activity. Norclo-
zapine was able to inhibit the BHT but with a higher IC90 of
125 mM, whereas clozapine N-oxide was ineffective at concentra-
tions up to 200 mM. Fluperlapine, clothiapine, loxapine, amoxa-
pine, and chlorpromazine, which have either anti-psychotic or
anti-depressant clinical utility, also inhibited the BHT, with the
most effective being chlorpromazine (IC90 20 mM). Fluperlapine
also displayed the same chemical epistasis phenotypes with the
efg1-T206E, db-cAMP, ras1-G13V, and gpa2-Q355L mutants as
clozapine (data not shown), suggesting that fluperlapine is acting
by a similar mechanism. It should be noted, however, that BHT
inhibition is not associated with all anti-psychotic or anti-
depressants that are receptor antagonists, as mirtazapine (seroto-
nin and histamine receptors), ketotifen (histamine receptors) and
amisulpride (dopamine D2 and D3 receptors) did not inhibit the
BHT at concentrations up to 200 mM.
Discussion
Taken together, the BHT inhibition and epistasis data (Table 1)
allow for several conclusions. CGP-37157 does not inhibit a
component of either the Cph1 or Efg1 pathway. CGP-37157 is
known toaffect calcium homeostasis through regulatingintracellular
Figure 4. Chemical epistasis with cAMP and ras1-G13V mutant. A, Wild-type strain SC5314 was incubated in the absence (white bars) and
presence (black bars) of 10 mM N
6,29-O-dibutyryl-cAMP (db-cAMP) for 6 h at 37uC. Quantification of morphological phenotypes was as in Figure 2.
Asterisks indicates a P value of ,0.05 compared to the corresponding –db-cAMP control. B, The ras1-G13V constitutively active mutant strain DH409
was incubated in Spider media with the indicated BHT inhibitors for 6 h at 37uC as in Figure 3. Asterisks indicates a P value of ,0.05 compared to the
corresponding wild-type SC5314 plus BHT inhibitor control.
doi:10.1371/journal.pone.0025395.g004
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single signaling pathway. TMB-8, FK-506, W-7, and nigericin are
also known to affect calcium homeostasis in the cell, either through
affecting calcium/calmodulin-dependent protein kinase [W-7; [44],
the calcineurin phosphatase [FK-506; [45], or intracellular calcium
levels [TMB-8; [46] and nigericin; [47]. Of these four BHT
inhibitors, only TMB-8 can block the BHT in Lee’s media, and only
FK-506 can block in GlcNAc media, suggesting that these four
inhibitors are blocking different pathways responding to different
growth signals. All four inhibitors are suppressed by overexpression
of the Cph1 transcription factor and by the efg1-T206E mutant.
Taken together, these data suggest that TMB-8, W-7, FK-506, and
nigericin affect multiple signaling pathways, including the Efg1 and
Cph1 pathways, presumably by affecting calcium homeostasis.
ETYA inhibited in Spider, Lee’s and GlcNAc media,
suggesting that it can block multiple signaling pathways like
CPG-37157. However, while ETYA was epistatic to ADH1pr-
CPH1 expression, the efg1-T206E mutant, and added db-cAMP,
it was not epistatic to the ras1-G13V or gpa2-Q355L constitutively
active mutants. Taken together, these data suggest that ETYA is
acting upstream of Ras1 and Gpa2 but not through the Efg1 or
Cph1 signaling pathways. ETYA is a member of the oxylipin
family of oxidized fatty acids and is the alkyne homolog of
arachidonic acid. It is a known inhibitor of mammalian
lipooxygenases (LOXs) and cyclooxygenases (COXs) [48,49],
which convert arachidonic acid to eicosanoids, such as prosta-
glandins and other bioactive lipids. ETYA has also been shown to
be a potent activator of the peroxisome proliferator-activated
receptor alpha (PPAR-alpha), a nuclear receptor transcription
factor that activates the expression of multiple genes involved in
the cellular uptake, activation, and beta-oxidation of fatty acids
[50–52]. In addition, ETYA has been shown to possess anti-
oxidant capabilities in mammalian and plant cells [53,54], and is
structurally similar to farnesol and farnesoic acid, two known
quorum-sensing molecules in C. albicans [55,56]. Therefore,
ETYA may be inhibiting the BHT through a variety of diverse
regulatory mechanisms. C. albicans cells produce a variety of
oxylipins, eicosanoids, and other bioactive lipids that regulate cell
Figure 5. Chemical epistasis with gpa2-Q355L mutant and ADH1pr-GPR1 overexpression. A, Wild-type strain SC5314 (white bars) and
gpa2-Q355L mutant strain HTC7 (black bars) were grown in Spider media with the indicated BHT inhibitors (100 mM final concentration) for 6 h at
37uC prior to quantification of morphological phenotype as in Figure 2. Asterisks indicates a P value of ,0.05 compared to corresponding wild-type
SC5314 plus BHT inhibitor control. B, The ADH1pr-GPR1 strain YTC014 was spotted onto Spider solid media containing either DMSO or clozapine
(,100 mM final concentration) and incubated for 7 days at 37uC.
doi:10.1371/journal.pone.0025395.g005
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60], but the mechanisms by which this regulation occur are
unknown. The absence of recognizable LOXs and COXs in the
annotated C. albicans genome compounds the uncertainty
surrounding the mechanism of action of ETYA in C. albicans.
A-3 was only effective in Spider media but was suppressed by
overexpression of the Cph1 transcription factor and by the efg1-
T206E mutant, suggesting that A-3 may be inhibiting a
component of both pathways. A-3 has a broad inhibitory spectrum
against protein kinases but seems to have better efficacy against
Figure 6. Clozapine and its bioactive structural derivatives inhibit the BHT. The indicated molecules were tested in the BHT morphological
assay in Spider media for 6 h at 37uC. Below each molecule name is their IC90 value (i.e., lowest concentration of molecule used at which .90%
budded cells were observed), which was determined using serial dilutions of the individual molecules. Those molecules with IC90 values over 200 mM
were not inhibitory in the BHT assay.
doi:10.1371/journal.pone.0025395.g006
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as the role of PKA in the Efg1 pathway is well established [16]. A-
3 may have inhibitory activity against one of the MAP kinases in
the Cph1 pathway as well, which will be tested in the future.
L-744,832 was inhibitory in both Spider and GlcNAc and was
suppressed by the efg1-T206E mutant but not by overexpression of
the Cph1 transcription factor, suggesting that it inhibits a
component of the Efg1 pathway. It was also suppressed by the
ras1-G13V mutant but not by the gpa2-Q355L mutant, suggesting
that it is acting at the level of Ras1. This is consistent with the fact
that L-744,832 is a known farnesyltransferase inhibitor [62] that
can block Ras function as well as other farnesylated proteins in the
cell. Interestingly, L-744,832 may be inhibiting a farnesylated
protein(s) that functions within the ill-defined GlcNAc pathway.
Clozapine and YC-1 were only inhibitory in Spider media
whereas GW-9662 and GW 5074 also blocked in Lee’s media. All
four BHT inhibitors were suppressed by the efg1-T206E mutant
but not by overexpression of the Cph1 transcription factor. These
data suggest that clozapine, GW-9662, GW 5074, and YC-1
inhibit components within the Efg1 signaling pathway. The target
of the guanylyl cyclase activator YC-1 in the Efg1 pathway is
unclear as there is no recognizable guanylyl cyclase encoded in the
C. albicans genome. GW 5074 effects were reversed by added db-
cAMP but not by the ras1-G13V or gpa2-Q355L constitutive
mutants, suggesting that GW 5074 is acting at a level between
Ras1 and adenylate cyclase. GW5074 inhibits the mammalian
cRaf-1 kinase [63], which functions downstream of the Ras
GTPase. Although a Raf-1-like kinase as not been identified in the
Efg1 pathway in C. albicans to date, these data would suggest that a
similar protein functions downstream of Ras1 in the Efg1 pathway
but not the Cph1 pathway.
Both clozapine and GW-9662 are mammalian receptor
antagonists. The epistasis data suggest that clozapine and GW-
9662 inhibit a component of the Efg1 pathway that is upstream of
the Gpa2 G-alpha subunit, possibly the Gpr1 G-protein-coupled
receptor (GPCR). The clozapine inhibitory effects seem to be
specific in that (i) structural derivatives that are active in
mammalian cells are inhibitory in C. albicans;( ii) the inactive
analog clozapine N-oxide is inactive in C. albicans; and (iii) three
other receptor antagonists (mirtazapine, ketotifen, and amisul-
pride) are not inhibitory in C. albicans. Although clozapine can
suppress the hyperfilamentation phenotype of overexpression of
Gpr1, it remains to be determined if clozapine directly binds to the
Gpr1 GPCR to inhibit its function, as it does with the mammalian
dopamine receptors.
From a structural perspective, the data from the clozapine
analogs suggest several things. The N-methyl group of clozapine is
important but not essential for it inhibitory function because
norclozapine had reduced efficacy but could still inhibit the BHT
and because amoxapine (IC90 40 mM) had comparable efficacy to
its methylated analog loxapine (IC90 50 mM). Also, replacement of
one of the nitrogens in the benzodiazepine ring system with sulfur
(clothapine and chlorpromazine) increases the efficacy about 2-
fold, which may be reflective of either increased binding avidity or
molecule stability.
Although all 16 BHT inhibitors were isolated in screens using
the carbon-limiting hyphal-inducing signal of Spider media,
implying they would be inhibiting a component of the Efg1
pathway, it is clear that some of the inhibitors have effects on other
signaling pathways as well. These effects may be indicative of
cross-talk between pathways or of common components that
function in multiple pathways. Identifying the C. albicans cellular
targets of these inhibitors should clarify these points in the future.
Materials and Methods
Growth Media and Strains
Protocols for the growth and maintenance of C. albicans strains
weredescribedpreviously[35,36].Thehyphal-inducingmediaused
in these studies were (i) carbon-limiting Spider medium [[7]; 1%
nutrient broth, 1% mannitol, 0.2% K2HPO4], (ii) YPD (1% yeast
extract, 2% peptone, and 2% dextrose)+10% (vol/vol) fetal calf
serum, (iii) minimal amino acids Lee’s medium [6]; contains the
amino acids alanine, leucine, lysine, methionine, phenylalanine,
proline,andthreonine+1%dextrose],and(iv) GlcNAc(NPK)media
[[24]; 0.5% GlcNAc, 0.5% peptone, 0.3% KH2PO4].
Table 1. Summary of BHT inhibition and chemical epistasis data.
Molecule Spider 10% serum Lee’s GlcNAc efg1-T206E ADH1pr-CPH1 db-cAMP ras1-G13V
gpa2-
Q355L Predicted Pathway
TMB-8 + 2 + 2 ++ NT NT NT multiple
W-7 + 22 2 ++ NT NT NT multiple
CGP-37157 + 2 ++ 2 2 222 multiple
FK-506 + 2 ++ 2 + NT NT NT multiple
Nigericin + 2 + 22 + NT NT NT multiple
A-3 + 22 2 ++ NT NT NT Efg1, Cph1
Clozapine + 22 2 + 2 +++ Efg1
GW-9662 + 2 + 2 + 22 ++ Efg1
L-744,832 + 22 ++ 22 + 2 Efg1
GW 5074 + 2 + 2 + 2 + 22 Efg1
YC-1 + 22 2 + 2 +++ Efg1
ETYA + 2 ++ 22 2 ++ multiple
In the Spider, 10% serum, Lee’s, and GlcNAc columns, ‘‘+’’ refers to statistically significant BHT inhibitory activity (P value of ,0.05 compared to the DMSO control; see
Figure 2), whereas ‘‘2’’ refers to no statistically significant BHT inhibitory activity (P value of .0.05 compared to the DMSO control). In the efg1-T206E, ADH1pr-CPH1, db-
cAMP, ras1-G13V, and gpa2-Q355L columns, ‘‘+’’ refers to the constitutively active mutant or db-cAMP being epistatic to the added BHT inhibitor, whereas ‘‘2’’ refers to
the added BHT inhibitor being epistatic to the constitutively active mutant or db-cAMP. NT, not tested.
doi:10.1371/journal.pone.0025395.t001
C. albicans BHT Inhibitors Block Multiple Pathways
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e25395The Candida albicans strains used in this study are listed in
Table 2. Strain AV55, which contains the efg1-T206E allele under
the control of the PCK1 promoter [41], was constructed by
transforming strain CAI4 (ura3::limm434/ura3::limm434; [64])
with linearized plasmid pDB2 [41], directing integration of
PCK1pr-efg1-T206E at the LEU2 locus.
BHT Inhibitors
All small molecule BHT inhibitors were dissolved in DMSO to
a stock concentration of 40 mM (except for nigericin, FK-506, and
L-744,832, which were dissolved to a stock concentration of
20 mM) and stored at 0uC. Molecules clozapine, clozapine-N-
oxide, norclozapine, clothiapine, fluperlapine, ketotifen, A-3, and
ETYA were purchased from BIOMOL International/Enzo Life
Sciences (Plymouth Meeting, PA); molecules TMB-8, GW 5074,
GW-9662, FK-506, loxapine, chlorpromazine, amoxapine, YC-1,
and N
6,29-O-dibutyryl-cAMP (db-cAMP) were purchased from
Sigma-Aldrich (St. Louis, MO); and molecules W-7, L-744,832,
amisulpride, mirtazapine, and CGP-37157 were purchased from
Tocris Bioscience (Ellisville, MO). Unless otherwise noted in the
text, all small molecules were used at a final concentration of
100 mM in liquid BHT and chemical epistasis assays.
BHT and chemical epistasis assays
The BHT morphology assay in different hyphal-inducing media
was performed as previously described [35]. C. albicans SC5314
cells were grown overnight in 5-ml cultures of YPD media at 30uC
to block hyphal formation. Cells were washed once with ddH2O
and an aliquot of cells was inoculated into YNB media (0.67%
yeast nitrogen base, 2% dextrose, and the required supplements of
uridine, histidine, and arginine, pH 7) and grown to O.D. of 1.0,
then washed once with ddH2O. Approximately 1610
4 cells were
then added to each of the four hyphal-inducing media and
incubated at 37uC for 6 h. After 6 h, the morphology of cells was
determined by light microscopy.
Quantification of BHT inhibition was accomplished by
counting the number of individual budded cells versus the number
of hyphae in the population as previously described [35]. More
than 100 cells were counted for each sample in duplicate and all
assays were repeated at least twice. Large-budded cells (i.e., buds
were comparable in size to the mother cells) were counted as two
cells, while small-budded cells (i.e., buds were smaller than the
mother cells) were counted as one cell. This method, which was
necessitated by the aggregation of budded cells that could not be
resolved by sonication, resulted in an underrepresentation of the
number of budded cells in the population. Individual hyphae were
counted as one cell, although the hyphae usually consisted of
multiple individual hyphal cells. This method, which was
necessitated by the inability to quantify individual cells within
hyphae, also resulted in an underrepresentation of the number of
hyphal cells in the population. The IC90 value for selected BHT
inhibitory molecule (i.e., lowest concentration of molecule used at
which .90% budded cells were observed) was determined using
serial dilutions of the individual molecules.
The chemical epistasis assays were performed similarly to the
BHT assays. For the efg1-T206E epistasis experiments, strain
AV55 was grown overnight in SC+AA ([65]; 0.67% yeast nitrogen
base plus amino acids) to de-repress the PCK1 promoter, followed
by incubation in Spider media with added BHT inhibitor (final
concentration 100 mM) for 6 h at 37uC. After 6 h, the morphology
of cells was determined by light microscopy. For the cAMP
epistasis experiments, strain SC5314 was incubated in Spider
media +/210 mM N
6,29-O-dibutyryl-cAMP (db-cAMP) for 6 h at
37uC. Epistasis experiments with the ras1-G13V and gpa2-Q355L
mutants were performed in Spider media for 6 h at 37uC.
Statistical analyses of the hyphal-inducing media experiments
and the efg1-T206E, ras1-G13V, and gpa2-Q355L epistasis
experiments were accomplished using One-way Analysis of
Variance (ANOVA) with a Dunnett post test. Statistical analysis
of the db-cAMP epistasis experiment was performed using a
Wilcoxon matched-pairs signed rank test. All tests were performed
using GraphPad Prism 3 software and data were considered
significant if the P value was ,0.05. In the hyphal-inducing media
experiments, the percentage of hyphae in wild-type SC5314 cells
grown in the different hyphal-inducing media plus BHT inhibitors
was compared to the mean of the percentage of hyphae in wild-
type SC5314 cells plus DMSO. For the efg1-T206E, ras1-G13V,
and gpa2-Q355L epistasis experiments, the percentage of hyphae
in mutant cells grown in Spider media plus BHT inhibitor was
compared to the mean of the percentage of hyphae in wild-type
SC5314 cells grown in Spider media plus BHT inhibitor. For the
db-cAMP epistasis experiments, the percentage of hyphae in wild-
type SC5314 cells grown in Spider media plus db-cAMP and BHT
inhibitor was compared to the mean of the percentage of hyphae
in wild-type SC5314 cells grown in Spider media plus BHT
inhibitor alone.
Hyperfilamentation on solid media assay
Either clozapine (125 ml of 40 mM solution in DMSO) or
DMSO alone were spread uniformly using glass beads onto Petri
plates containing 25 ml of solid Spider media. The plates were
then incubated at 30uC for 3 h and at room temperature for 2 h to
ensure absorption. Strain YTC014, which has the GPR1 gene
expressed under the control of the constitutive ADH1 promoter
(ADH1pr-GPR1), was grown overnight in YEPD, transferred to
YNB as above, and then serially diluted onto the clozapine-infused
plates and DMSO-infused plates. The inoculated plates were
wrapped in parafilm and incubated for 7 days at 37uC. The
Table 2. C. albicans strains.
Strain Genotype Reference
SC5314 Wild-type clinical isolate [66]
AV55 ura3::limm434/ura3::limm434; LEU2::pCK1-efg1-T206E::URA3 This study
DH409 ura3::limm434/ura3; ras1-G13V [56]
HTC7 ura3::limm434/ura3::limm434; TRP1/TRP1::ADH1pr-gpa2-Q355L::URA3 [19]
YTC014 ura3::limm434/ura3::limm434; TRP1/TRP1::ADH1pr-GPR1-URA3 [19]
CDH72-1 ura3/ura3 cph1D::hisG/cph1D::hisG; ADH1pr-CPH1 [13]
doi:10.1371/journal.pone.0025395.t002
C. albicans BHT Inhibitors Block Multiple Pathways
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e25395presence of hyphal growth at the colony edges was determined
using an inverted microscope.
Microscopy
For the BHT and chemical epistasis assays, sample slides were
viewed on a Nikon Eclipse E400 light microscope with a 106
objective and viewed through XF100 filter. Images were obtained
by using a Spot RT Monochrome camera and viewed with Spot
Advanced software (Diagnostic Instruments, Inc., Sterling
Heights, MI).
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